- Home
- TWFG vs ERAS Comparison
TWFG vs ERAS Comparison
Compare TWFG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- ERAS
- Stock Information
- Founded
- TWFG 2001
- ERAS 2018
- Country
- TWFG United States
- ERAS United States
- Employees
- TWFG N/A
- ERAS N/A
- Industry
- TWFG
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- TWFG
- ERAS Health Care
- Exchange
- TWFG NYSE
- ERAS Nasdaq
- Market Cap
- TWFG 521.8M
- ERAS 484.4M
- IPO Year
- TWFG 2024
- ERAS 2021
- Fundamental
- Price
- TWFG $29.37
- ERAS $1.39
- Analyst Decision
- TWFG Buy
- ERAS Strong Buy
- Analyst Count
- TWFG 8
- ERAS 6
- Target Price
- TWFG $35.57
- ERAS $4.83
- AVG Volume (30 Days)
- TWFG 68.7K
- ERAS 822.8K
- Earning Date
- TWFG 08-12-2025
- ERAS 08-11-2025
- Dividend Yield
- TWFG N/A
- ERAS N/A
- EPS Growth
- TWFG N/A
- ERAS N/A
- EPS
- TWFG N/A
- ERAS N/A
- Revenue
- TWFG $211,440,000.00
- ERAS N/A
- Revenue This Year
- TWFG $23.90
- ERAS N/A
- Revenue Next Year
- TWFG $22.60
- ERAS N/A
- P/E Ratio
- TWFG N/A
- ERAS N/A
- Revenue Growth
- TWFG 18.57
- ERAS N/A
- 52 Week Low
- TWFG $22.93
- ERAS $1.01
- 52 Week High
- TWFG $36.85
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- ERAS 41.47
- Support Level
- TWFG N/A
- ERAS $1.53
- Resistance Level
- TWFG N/A
- ERAS $1.81
- Average True Range (ATR)
- TWFG 0.00
- ERAS 0.12
- MACD
- TWFG 0.00
- ERAS -0.02
- Stochastic Oscillator
- TWFG 0.00
- ERAS 10.64
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.